QQQ   414.73 (-2.05%)
AAPL   165.11 (-1.16%)
MSFT   399.28 (-1.23%)
META   479.55 (-4.43%)
GOOGL   153.82 (-1.40%)
AMZN   174.34 (-2.72%)
TSLA   146.98 (-1.97%)
NVDA   769.00 (-9.18%)
AMD   146.18 (-5.74%)
NIO   3.81 (-4.75%)
BABA   69.05 (+0.25%)
T   16.45 (+0.73%)
F   12.11 (+0.41%)
MU   106.48 (-4.87%)
GE   148.44 (-2.94%)
CGC   8.05 (+2.81%)
DIS   112.31 (-0.11%)
AMC   3.13 (+7.19%)
PFE   25.96 (+2.24%)
PYPL   61.96 (-0.23%)
XOM   119.97 (+1.22%)
QQQ   414.73 (-2.05%)
AAPL   165.11 (-1.16%)
MSFT   399.28 (-1.23%)
META   479.55 (-4.43%)
GOOGL   153.82 (-1.40%)
AMZN   174.34 (-2.72%)
TSLA   146.98 (-1.97%)
NVDA   769.00 (-9.18%)
AMD   146.18 (-5.74%)
NIO   3.81 (-4.75%)
BABA   69.05 (+0.25%)
T   16.45 (+0.73%)
F   12.11 (+0.41%)
MU   106.48 (-4.87%)
GE   148.44 (-2.94%)
CGC   8.05 (+2.81%)
DIS   112.31 (-0.11%)
AMC   3.13 (+7.19%)
PFE   25.96 (+2.24%)
PYPL   61.96 (-0.23%)
XOM   119.97 (+1.22%)
QQQ   414.73 (-2.05%)
AAPL   165.11 (-1.16%)
MSFT   399.28 (-1.23%)
META   479.55 (-4.43%)
GOOGL   153.82 (-1.40%)
AMZN   174.34 (-2.72%)
TSLA   146.98 (-1.97%)
NVDA   769.00 (-9.18%)
AMD   146.18 (-5.74%)
NIO   3.81 (-4.75%)
BABA   69.05 (+0.25%)
T   16.45 (+0.73%)
F   12.11 (+0.41%)
MU   106.48 (-4.87%)
GE   148.44 (-2.94%)
CGC   8.05 (+2.81%)
DIS   112.31 (-0.11%)
AMC   3.13 (+7.19%)
PFE   25.96 (+2.24%)
PYPL   61.96 (-0.23%)
XOM   119.97 (+1.22%)
QQQ   414.73 (-2.05%)
AAPL   165.11 (-1.16%)
MSFT   399.28 (-1.23%)
META   479.55 (-4.43%)
GOOGL   153.82 (-1.40%)
AMZN   174.34 (-2.72%)
TSLA   146.98 (-1.97%)
NVDA   769.00 (-9.18%)
AMD   146.18 (-5.74%)
NIO   3.81 (-4.75%)
BABA   69.05 (+0.25%)
T   16.45 (+0.73%)
F   12.11 (+0.41%)
MU   106.48 (-4.87%)
GE   148.44 (-2.94%)
CGC   8.05 (+2.81%)
DIS   112.31 (-0.11%)
AMC   3.13 (+7.19%)
PFE   25.96 (+2.24%)
PYPL   61.96 (-0.23%)
XOM   119.97 (+1.22%)

Verastem (VSTM) Competitors

$9.86
-0.37 (-3.62%)
(As of 03:32 PM ET)

VSTM vs. XOMA, VNDA, RIGL, RGLS, LXRX, EBS, OPK, INVA, MNKD, and NKTR

Should you be buying Verastem stock or one of its competitors? The main competitors of Verastem include XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Rigel Pharmaceuticals (RIGL), Regulus Therapeutics (RGLS), Lexicon Pharmaceuticals (LXRX), Emergent BioSolutions (EBS), OPKO Health (OPK), Innoviva (INVA), MannKind (MNKD), and Nektar Therapeutics (NKTR). These companies are all part of the "pharmaceutical preparations" industry.

Verastem vs.

XOMA (NASDAQ:XOMA) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

XOMA has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, Verastem has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500.

XOMA currently has a consensus price target of $74.00, suggesting a potential upside of 200.94%. Verastem has a consensus price target of $28.79, suggesting a potential upside of 181.39%. Given Verastem's higher possible upside, analysts clearly believe XOMA is more favorable than Verastem.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XOMA
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Verastem
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

Verastem has a net margin of 0.00% compared to Verastem's net margin of -886.91%. Verastem's return on equity of -25.17% beat XOMA's return on equity.

Company Net Margins Return on Equity Return on Assets
XOMA-886.91% -25.17% -17.08%
Verastem N/A -127.00%-54.73%

95.9% of XOMA shares are held by institutional investors. Comparatively, 88.4% of Verastem shares are held by institutional investors. 7.2% of XOMA shares are held by insiders. Comparatively, 2.9% of Verastem shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Verastem received 168 more outperform votes than XOMA when rated by MarketBeat users. However, 65.74% of users gave XOMA an outperform vote while only 65.20% of users gave Verastem an outperform vote.

CompanyUnderperformOutperform
XOMAOutperform Votes
426
65.74%
Underperform Votes
222
34.26%
VerastemOutperform Votes
594
65.20%
Underperform Votes
317
34.80%

In the previous week, Verastem had 3 more articles in the media than XOMA. MarketBeat recorded 4 mentions for Verastem and 1 mentions for XOMA. Verastem's average media sentiment score of 0.59 beat XOMA's score of 0.25 indicating that XOMA is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
XOMA
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Verastem
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

XOMA has higher revenue and earnings than Verastem. XOMA is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XOMA$4.76M60.13-$40.83M-$4.04-6.09
Verastem$2.60M99.59-$87.37M-$4.10-2.49

Summary

XOMA beats Verastem on 11 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VSTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VSTM vs. The Competition

MetricVerastemPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$274.33M$6.46B$4.80B$7.48B
Dividend YieldN/A3.13%2.99%4.00%
P/E Ratio-2.497.21180.9614.13
Price / Sales99.59306.592,419.1489.07
Price / CashN/A29.1046.9034.88
Price / Book4.515.424.584.19
Net Income-$87.37M$141.35M$103.64M$214.15M
7 Day Performance-9.47%-5.73%-3.81%-3.31%
1 Month Performance-9.55%-8.00%-5.31%-3.82%
1 Year Performance115.82%-5.68%7.34%3.74%

Verastem Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XOMA
XOMA
3.4816 of 5 stars
$24.38
+0.2%
$74.00
+203.5%
+26.3%$283.78M$4.76M-6.0313Positive News
VNDA
Vanda Pharmaceuticals
3.255 of 5 stars
$4.05
-0.2%
N/A-20.2%$233.04M$192.64M81.02203News Coverage
RIGL
Rigel Pharmaceuticals
1.7822 of 5 stars
$1.14
-0.9%
$5.81
+409.9%
-13.9%$199.96M$116.88M-7.60147Positive News
RGLS
Regulus Therapeutics
2.322 of 5 stars
$2.56
-7.9%
$7.25
+183.2%
+80.5%$167.58MN/A-1.6130Analyst Report
LXRX
Lexicon Pharmaceuticals
0.9337 of 5 stars
$1.70
-9.6%
$5.00
+195.0%
-37.3%$417.38M$1.20M-2.12285Gap Down
EBS
Emergent BioSolutions
3.7656 of 5 stars
$1.95
-1.5%
$5.00
+156.4%
-83.0%$102.16M$1.05B-0.131,600Positive News
OPK
OPKO Health
4.7402 of 5 stars
$1.21
-1.6%
$3.73
+207.9%
-13.4%$843.36M$863.50M-4.843,930Analyst Revision
Gap Down
INVA
Innoviva
4.1526 of 5 stars
$14.47
+0.5%
$22.50
+55.5%
+28.9%$914.94M$310.46M6.64112Positive News
MNKD
MannKind
2.0935 of 5 stars
$4.05
-1.7%
$8.00
+97.5%
-4.2%$1.10B$198.96M-81.00411Positive News
NKTR
Nektar Therapeutics
3.8141 of 5 stars
$1.49
-5.1%
$3.50
+134.9%
+42.3%$273.59M$90.12M-1.02137Gap Down

Related Companies and Tools

This page (NASDAQ:VSTM) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners